Whittier Trust Co. of Nevada Inc. Sells 5,507 Shares of Pfizer Inc. (NYSE:PFE)

Whittier Trust Co. of Nevada Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 4.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 123,620 shares of the biopharmaceutical company’s stock after selling 5,507 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Pfizer were worth $3,278,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Douglass Winthrop Advisors LLC boosted its holdings in Pfizer by 78.2% during the 4th quarter. Douglass Winthrop Advisors LLC now owns 85,776 shares of the biopharmaceutical company’s stock worth $2,276,000 after acquiring an additional 37,653 shares during the last quarter. Northwest & Ethical Investments L.P. boosted its holdings in Pfizer by 0.6% during the fourth quarter. Northwest & Ethical Investments L.P. now owns 265,072 shares of the biopharmaceutical company’s stock worth $7,032,000 after purchasing an additional 1,541 shares during the last quarter. Berkeley Capital Partners LLC grew its position in Pfizer by 2.3% in the 4th quarter. Berkeley Capital Partners LLC now owns 69,190 shares of the biopharmaceutical company’s stock worth $1,836,000 after purchasing an additional 1,531 shares in the last quarter. Fiduciary Group LLC lifted its position in shares of Pfizer by 36.5% during the 4th quarter. Fiduciary Group LLC now owns 117,669 shares of the biopharmaceutical company’s stock worth $3,122,000 after buying an additional 31,479 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in shares of Pfizer by 93.3% in the 4th quarter. Teacher Retirement System of Texas now owns 1,969,261 shares of the biopharmaceutical company’s stock worth $52,244,000 after buying an additional 950,358 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PFE. Citigroup dropped their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Stock Up 0.1 %

PFE stock opened at $26.20 on Friday. The stock has a 50-day simple moving average of $26.17 and a two-hundred day simple moving average of $27.05. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm has a market capitalization of $148.61 billion, a PE ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the company earned $0.10 earnings per share. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.